Press Releases from http://www.marketresearchreports.biz/analysis/244676 (1 total)
Frontier Pharma: Pain - Identifying And Commercializing First-In-Class Innovatio …
Large and Innovative Pipeline
The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by…
